On June 29, 2023, Dr. Audrey Kunin advised NovaBay Pharmaceuticals, Inc. of her decision to retire and resign from her position as the Companyâs Chief Product Officer effective as of November 5, 2023, the natural expiration of her Executive Employment Agreement, dated November 5, 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0804 USD | -9.97% | -15.28% | -60.59% |
May. 09 | Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Reports Q1 Revenue $2.63M, vs. Street Est of $3.28M | MT |
May. 09 | Transcript : NovaBay Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024 |
EPS Revisions
- Stock Market
- Equities
- NBY Stock
- News NovaBay Pharmaceuticals
- Novabay Pharmaceuticals, Inc. Announces Audrey Kunin to Retire and Resign from Her Position as Chief Product Officer Effective as of November 5, 2023